# Â Canada based MustGrow Biologics Corp. records sales revenue of $0.8 Mn in Q3-2025

26 November 2025 | News

**Company registered Gross profit of $180,555 equating to a 22.9 per cent gross profit margin in Q3-2025 (up from 20.9 per cent in Q2-2025).**

**Company registered Gross profit of $180,555 equating to a 22.9 per cent gross profit margin in Q3-2025 (up from 20.9 per cent in Q2-2025).**

Canada based MustGrow Biologics Corp., a leading provider of biological and regenerative agriculture solutions, announced its operating and financial results for the three months ended September 30, 2025.Â

**Key Financial Highlights:**

Sales revenue of $0.8 million was recorded in Q3-2025 vs. no revenue in Q3-2024

Gross profit of $180,555 equating to a 22.9 per cent gross profit margin in Q3-2025 (up from 20.9 per cent in Q2-2025). Cash and equivalents on hand as at September 30, 2025 was $3.3 million with inventory of $1.9 million.

"The third calendar quarter is typically the lowest product revenue â??shoulder seasonâ?? for Canadian agriculture as farmers are harvesting their crops rather than purchasing input products. MustGrowâ??s gross profit margin improvement over the second quarter resulted from higher margin product sales through our Canadian sales and distribution division, NexusBioAg.â?• stated Corey Giasson, President and CEO of MustGrow.

"As mentioned in previous earnings calls, Q1 and Q4 are traditionally stronger sales periods, as Canadian farmers purchase crop inputs. We are looking forward to a strong finish to the year in Q4 and also Q1-2026 as farmers purchase products in preparation for the 2026 growing season", he added.

The Company continues to focus on capital allocation that generates revenue growth of both its NexusBioAg Canadian sales and distribution business and TerraSanteTM biofertility product sales in the U.S.